caa a22 4500 469078170 CHVBK 20180323132941.0 cr unu---uuuuu 170328e19920901xx s 000 0 eng 10.1007/BF00173547 doi (NATIONALLICENCE)springer-10.1007/BF00173547 CP-96,345, a non-peptide antagonist of substance P. III. Cardiovascular effects in mammals unrelated to actions on substance P receptors [Elektronische Daten] [J. Donnerer, U. Stark, H. Tritthart, F. Lembeck] Summary: The cardiovascular effects of CP-96,345, a non-peptide antagonist of substance P, were analyzed in vivo and in vitro. In the anaesthetized rat, the i.v. injection of 3 µmolkg−1 of CP-96,345 induced a fall in mean arterial blood pressure and a reduction in heart rate. Similar effects were obtained with the enantiomer CP-96,344 ((2R,3R)-cis-isomer of CP-96,345) which does not interact with substance P receptors. Both enantiomers, at a concentration of 10 gM, decreased the beating frequency of the isolated atria and of the isolated perfused heart of the guinea-pig to a similar extent, and caused transient coronary dilatation. CP-96,345 (10 µM) decreased the spontaneous sinus rate, prolonged the atrioventricularnodal conduction interval and the His-bundle conduction interval of the perfused guinea-pig heart. The intraventricular spread of conduction was markedly inhibited. During programmed stimulation 10 min after the beginning of the drug application, the effective refractory periods evaluated by stimulation with premature beats, as well as rate dependent effective refractory periods, of the atrioventricular node, of the atrial and of the ventricular myocardium, were prolonged. Sinus node recovery time was also prolonged. It was concluded that these cardiac effects of CP-96,345 were not caused by an action of the compound on substance P receptors. Springer-Verlag, 1992 Rat mean arterial blood pressure nationallicence Isolated guinea-pig heart nationallicence ECG recording nationallicence CP-96,345 nationallicence Substance P-antagonist nationallicence Donnerer J. Institut für Experimentelle und Klinische Pharmakologie, Austria aut Stark U. Institut für Medizinische Physik und Biophysik, Universität Graz, A-8010, Graz, Austria aut Tritthart H. Institut für Medizinische Physik und Biophysik, Universität Graz, A-8010, Graz, Austria aut Lembeck F. Institut für Experimentelle und Klinische Pharmakologie, Austria aut Naunyn-Schmiedeberg's Archives of Pharmacology Springer-Verlag 346/3(1992-09-01), 328-332 0028-1298 346:3<328 1992 346 210 https://doi.org/10.1007/BF00173547 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00173547 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Donnerer J. Institut für Experimentelle und Klinische Pharmakologie, Austria aut NATIONALLICENCE 700 1- Stark U. Institut für Medizinische Physik und Biophysik, Universität Graz, A-8010, Graz, Austria aut NATIONALLICENCE 700 1- Tritthart H. Institut für Medizinische Physik und Biophysik, Universität Graz, A-8010, Graz, Austria aut NATIONALLICENCE 700 1- Lembeck F. Institut für Experimentelle und Klinische Pharmakologie, Austria aut NATIONALLICENCE 773 0- Naunyn-Schmiedeberg's Archives of Pharmacology Springer-Verlag 346/3(1992-09-01), 328-332 0028-1298 346:3<328 1992 346 210 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer